uniQure Q2 net loss $68.5M; cash $628.6M; AMT-130 shows preservation of function

uniQure N.V.

2023-Q2 EPS reported -$3.06 revenue$7,747,000

Revenue $2.4M (up from $0.5M YoY); net loss $1.44/share vs $0.84 loss YoY.
Cash $628.6M (excl. $100M milestone from HEMGENIX 1st US sale received July 2023).
AMT-130 interim data: preserved clinical function vs natural history; both doses well-tolerated.
Sale of HEMGENIX royalty for up to $400M; $375M upfront received.
Appointed Walid Abi-Saab, M.D. as CMO and Jeannette Potts as CLO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

uniQure N.V. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 1, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023, and highlighting company progress.

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-23-086393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.